Myokine Levels in Relation to Bone Markers and Adipokines in Children with Prader-Willi Syndrome During Growth Hormone Therapy and Dietary Intervention.

Children with PWS had significantly lower lean mass and a higher fat mass to lean mass ratio compared to healthy controls.

• Study included 26 children with PWS and 26 age-matched healthy controls.
• Lean mass was significantly lower in the PWS group (p = 0.047).
• Fat mass/lean mass ratio was significantly higher in the PWS group (p < 0.001).
• Children with PWS were undergoing growth hormone therapy and dietary interventions and were classified as normal-weight.

Irisin levels were significantly lower in children with PWS compared to healthy controls.

• Irisin levels were lower in the PWS group (p = 0.031).
• Myostatin (MSTN) levels were similar between the PWS and control groups.
• Serum levels were measured using immunoenzymatic assays.

In PWS patients, irisin positively correlated with bone alkaline phosphatase and negatively correlated with carboxylated osteocalcin and periostin.

• Irisin positively correlated with bone alkaline phosphatase (BALP) (p = 0.025).
• Irisin negatively correlated with carboxylated osteocalcin (Gla-OC) (p = 0.041).
• Irisin negatively correlated with periostin (p = 0.005).
• These correlations were observed specifically in the PWS patient group.

Myostatin was positively associated with proinsulin and negatively associated with lean mass in PWS patients.

• MSTN was positively associated with proinsulin (p = 0.001).
• MSTN was negatively associated with lean mass (p = 0.015).
• The negative association between MSTN and lean mass may impair muscle development in PWS.

Osteocalcin concentration was lower in the PWS group and positively correlated with lean mass.

• Osteocalcin (OC) concentration was lower in the PWS group compared to controls.
• OC correlated positively with lean mass (p = 0.052).
• Both total osteocalcin (OC) and carboxylated osteocalcin (Gla-OC) were measured using immunoenzymatic assays.

The study assessed a comprehensive panel of myokines, bone markers, and adipokines in PWS children using immunoenzymatic assays.

• Serum levels of irisin, myostatin, fibroblast growth factor-2, IGF-I, IGF-binding protein-2, BALP, OC, Gla-OC, periostin, soluble RANKL, tartrate-resistant acid phosphatase 5b, leptin/soluble leptin receptor, adiponectin, and proinsulin were measured.
• All measurements were performed using immunoenzymatic assays.
• The study population consisted of 26 PWS children undergoing GH therapy and dietary intervention and 26 age-matched healthy controls.
• Data on the interplay between muscle, bone, and adipose tissue metabolism in normal-weight PWS children undergoing GH therapy and dietary interventions were described as limited prior to this study.

Imbalances in myokine, osteokine, and adipokine profiles in PWS children may contribute to future metabolic disorders.

• Reduced irisin and osteocalcin levels, along with the negative association between MSTN and lean mass, were identified as potentially impairing muscle development and bone metabolism.
• These imbalances could contribute to future metabolic disorders in patients with PWS.
• Children with PWS exhibit altered myokine, osteokine, and adipokine profiles as well as differences in body composition.